肾功能、肾功能下降与腹主动脉瘤风险:斯德哥尔摩肌酐测量(SCREAM)项目
该观察性研究利用2011至2021年斯德哥尔摩居民完整医疗记录,纳入1 586 410名无腹主动脉瘤(AAA)且接受常规肌酐检测者,分析估算肾小球滤过率(eGFR)及年下降幅度与AAA发病风险的关系。中位随访7.6年,5 313人(0.34%)发生AAA,其中321人(0.02%)为致死性AAA。多变量分析显示,较低eGFR及较快eGFR下降均与AAA风险升高相关,致死性AAA风险升高更明显。
要点
- 与eGFR 90相比,eGFR 30时AAA的HR为1.24,致死性AAA的HR为2.51。
- 与eGFR 90相比,eGFR 15时AAA的HR为1.49,致死性AAA的HR为3.73。
- eGFR年下降1至3 mL/min/year者AAA事件率较稳定者高15%(HR 1.15)。
核心结论
- 在该观察性研究中,单次eGFR及较快的eGFR下降均与发生AAA的风险相关。
- 慢性肾脏病程度更重或eGFR下降更快者,AAA尤其是致死性AAA的发生率更高。
研究设计与样本
- 该研究为观察性研究,使用2011至2021年斯德哥尔摩居民完整医疗记录。
- 纳入无AAA且接受常规肌酐检测的居民,共1 586 410人,平均年龄48岁,女性占53%,中位eGFR 96 mL/min/1.73 m2。
- 采用Cox回归分析,校正年龄、性别、合并症及正在使用的药物。
- 分析单次eGFR或一年内eGFR变化与新发AAA诊断(包括完整及破裂)和致死性AAA(AAA后30天内死亡)发生率的关系。
主要发现
- 中位随访7.6年,5 313人(0.34%)发生AAA,其中321人(0.02%)为致死性AAA。
- 与eGFR 90 mL/min/1.73 m2相比,eGFR 30 mL/min/1.73 m2者AAA的HR为1.24(95%CI 1.09-1.40),致死性AAA的HR为2.51(95%CI 1.67-3.75)。
- 与eGFR 90 mL/min/1.73 m2相比,eGFR 15 mL/min/1.73 m2者AAA的HR为1.49(95%CI 1.19-1.86),致死性AAA的HR为3.73(95%CI 2.04-6.81)。
- 分别分析时,完整及破裂AAA的风险结果相似。
- 在638 959名有重复eGFR检测的参与者中,3 447人(0.54%)发生AAA事件,其中217人(0.04%)为致死性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Low estimated glomerular filtration rate (eGFR) increases the risk of arterial diseases, possibly including abdominal aortic aneurysm (AAA). This study explored the relationship between eGFR (2008 CKD-EPI equation), annual eGFR decline, and subsequent risk of developing AAA in a large, community based sample. METHODS: This was an observational study using complete healthcare records of Stockholm residents free from AAA who underwent routine creatinine testing during 2011 - 2021. Cox regression, adjusted for age, sex, comorbidities, and ongoing medications, was used to analyse the association between a single point eGFR or the change in eGFR within a year and the rate of both a de novo AAA diagnosis (both intact and ruptured) and fatal AAA (i.e., AAA followed by death within 30 days). RESULTS: The study included 1 586 410 participants (mean age 48 years; 53% female; median eGFR 96 mL/min/1.73 m2). During a median follow up of 7.6 years, 5 313 participants (0.34%) experienced AAA, of which 321 (0.02%) were fatal. In multivariable analyses, compared with eGFR 90 mL/min/1.73 m2, the rates of AAA events were higher across lower eGFRs: for eGFR 30 mL/min/1.73 m2, the hazard ratio (HR) of AAA was 1.24 (95% confidence interval [CI] 1.09 - 1.40) and of fatal AAA was 2.51 (95% CI 1.67 - 3.75); for eGFR 15 mL/min/1.73 m2, the HR of AAA was 1.49 (95% CI 1.19 - 1.86) and of fatal AAA was 3.73 (95% CI 2.04 - 6.81). When analysed separately, the results were similar for intact and ruptured AAA risk. Among the 638 959 participants who had repeated eGFR tests, 3 447 (0.54%) experienced AAA events, of which 217 (0.04%) were fatal. Compared with stable eGFR (change -1 to 1 mL/min/year), the rate of AAA events was 15% higher (HR 1.15, 95% CI 1.05 - 1.26) in participants with an eGFR decline of 1 to 3 mL/min/year and 46% higher (HR 1.46, 95% CI 1.16 - 1.84) in those with an eGFR decline of > 3 mL/min/year. CONCLUSION: In this observational study, both a single point eGFR and a faster eGFR decline were associated with the risk of experiencing AAA. The incidence of AAA, and particularly fatal AAA, was higher in individuals with greater severity of chronic kidney disease or faster eGFR decline.
引用
- Tanaka S, Bosi A, Fu EL, et al. Kidney Function, Kidney Function Decline, and the Risk of Abdominal Aortic Aneurysm: The Stockholm CREAtinine Measurements (SCREAM) Project. Eur J Vasc Endovasc Surg. 2024. PMID: 39706328. doi:10.1016/j.ejvs.2024.12.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。